ANDA 202683, held by Orbion Pharms. Aripiprazole.
As of Nov 16, 2026, ANDA 202683 (Aripiprazole), held by Orbion Pharms, was first approved by FDA on May 23, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2017 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
| Dec 11, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 11, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 23, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters